With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...